SCHEMBL12377084

SCHEMBL12377084

CCc1cccc(-c2cccc(CNC)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 8/20 0.66
EPHX2 P34913 1/20 0.62
HTR7 P34969 1/20 0.54
BCL2 P10415 1/20 0.50
KDM4E B2RXH2 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
NOS1 P29475 3/20 0.46
PRKACA P17612 1/20 0.46
PRKACG P22612 1/20 0.46
PRKACB P22694 1/20 0.46
AKT2 P31751 1/20 0.46
PTGS2 P35354 1/20 0.45
IDO1 P14902 1/20 0.45
NISCH Q9Y2I1 1/20 0.44
NOS3 P29474 2/20 0.43
CARM1 Q86X55 1/20 0.42
NOTUM Q6P988 1/20 0.41
CHRM3 P20309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8441355 0.90 KDM4E (0.54) PRMT6EPHX2HTR7KDM4ECYP3A4
SCHEMBL1252083 0.86 PRMT6 (0.73) PRMT6EPHX2HTR7KDM4ECYP3A4
SCHEMBL5547358 0.85 BCL2 (0.62) PRMT6EPHX2BCL2PTGS2IDO1
SCHEMBL29489424 0.85 BCL2 (0.62) PRMT6EPHX2BCL2PTGS2IDO1
SCHEMBL8986195 0.82 PRMT6 (0.64) PRMT6EPHX2HTR7KDM4ECYP3A4
Water SCHEMBL9719807 0.81 BCL2 (0.65) PRMT6BCL2PTGS2IDO1NISCH
SCHEMBL12305657 0.81 PRMT6 (0.62) PRMT6EPHX2HTR7KDM4ECYP3A4
SCHEMBL1697126 0.80 MAPT (0.64) PRMT6EPHX2HTR7KDM4ECYP3A4
SCHEMBL14676172 0.79 PRMT6 (1.00) PRMT6EPHX2HTR7CYP3A4NOS1
SCHEMBL6414198 0.79 PRMT6 (0.65) PRMT6EPHX2HTR7KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008440-B2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery TRANZYME PHARMA INC. (CA) 2011-08-30 US disclosed
US-20070117154-A1 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117154-A1 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents F2, BCAT1, DAO PRMT6 401/4885EPHX2 1524/4885HTR7 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.